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Abstract Immune cells infiltrating tumors can have important impact on tumor progression and
response to therapy. We present an efficient algorithm to simultaneously estimate the fraction of
cancer and immune cell types from bulk tumor gene expression data. Our method integrates novel
gene expression profiles from each major non-malignant cell type found in tumors, renormalization
based on cell-type-specific mRNA content, and the ability to consider uncharacterized and possibly
highly variable cell types. Feasibility is demonstrated by validation with flow cytometry,
immunohistochemistry and single-cell RNA-Seq analyses of human melanoma and colorectal tumor
specimens. Altogether, our work not only improves accuracy but also broadens the scope of
absolute cell fraction predictions from tumor gene expression data, and provides a unique novel




Tumors form complex microenvironments composed of various cell types such as cancer, immune,
stromal and endothelial cells (Hanahan and Weinberg, 2011; Joyce and Fearon, 2015). Immune
cells infiltrating the tumor microenvironment play a major role in shaping tumor progression,
response to (immuno-)therapy and patient survival (Fridman et al., 2012). Today, gene expression
analysis is widely used to characterize tumors at the molecular level. As a consequence, tumor gene
expression profiles from tens of thousands of patients are available across all major tumor types in
databases such as Gene Expression Omnibus (GEO [Edgar et al., 2002]) or The Cancer Genome
Atlas (TCGA [Hoadley et al., 2014]). Unfortunately, flow cytometry or immunohistochemistry (IHC)
measurements to quantify the number of both malignant and tumor-infiltrating immune cells are
rarely performed for samples analyzed at the gene expression level. Therefore, to correctly interpret
these data in particular from an immuno-oncology point of view (Angelova et al., 2015;
Gentles et al., 2015; Hackl et al., 2016; Li et al., 2016; Linsley et al., 2015; Rooney et al., 2015;
S¸enbabaog˘lu et al., 2016; Zheng et al., 2017), reliable and carefully validated bioinformatics tools
are required to infer the fraction of cancer and immune cell types from bulk tumor gene expression
data.
To this end, diverse bioinformatics methods have been developed. Some aim at estimating tumor
purity based on copy number variation (Carter et al., 2012; Li and Li, 2014), or expression data
(Ahn et al., 2013; Clarke et al., 2010; Quon et al., 2013; Yoshihara et al., 2013), but do not pro-
vide information about the different immune cell types. Others focus on predicting the relative
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proportions of cell types by fitting reference gene expression profiles from sorted cells (Gong and
Szustakowski, 2013; Li et al., 2016; Newman et al., 2015; Qiao et al., 2012) or with the help of
gene signatures (Becht et al., 2016; Zhong et al., 2013). These approaches have been recently
applied to cancer genomics data to investigate the influence of immune infiltrates on survival or
response to therapy (Charoentong et al., 2017; Gentles et al., 2015; S¸enbabaog˘lu et al., 2016) or
predict potential targets for cancer immunotherapy (Angelova et al., 2015; Li et al., 2016). How-
ever, none of these methods provides quantitative information about both cancer and non-malig-
nant cell type proportions directly from tumor gene expression profiles. In addition, reference gene
expression profiles used in previous studies have been mainly obtained from circulating immune cells
sorted from peripheral blood and were generally based on microarrays technology. Finally, several
of these approaches have not been experimentally validated in solid tumors from human patients.
Here, we developed a robust approach to simultaneously Estimate the Proportion of Immune and
Cancer cells (EPIC) from bulk tumor gene expression data. EPIC is based on a unique collection of
RNA-Seq reference gene expression profiles from either circulating immune cells or tumor- infiltrat-
ing non-malignant cell types (i.e., immune, stromal and endothelial cells). To account for the high
variability of cancer cells across patients and tissue of origin, we implemented in our algorithm the
ability to consider uncharacterized, possibly highly variable, cell types. To validate our predictions in
human solid tumors, we first analyzed melanoma samples with both flow cytometry and RNA-Seq.
We then collected publicly available IHC and single-cell RNA-Seq data of colorectal and melanoma
tumors. All three validation datasets showed that very accurate predictions of both cancer and non-
malignant cell type proportions could be obtained even in the absence of a priori information about
cancer cells.
Results
Reference gene expression profiles from circulating and tumor-
infiltrating cells
EPIC incorporates reference gene expression profiles from each major immune and other non-malig-
nant cell type to model bulk RNA-Seq data as a superposition of these reference profiles
(Figure 1A,B). To tailor our predictions to recent gene expression studies, we first collected and
curated RNA-Seq profiles of various human innate and adaptive circulating immune cell types
eLife digest Malignant tumors do not only contain cancer cells. Normal cells from the body also
infiltrate tumors. These often include a variety of immune cells that can help detect and kill cancer
cells. Many evidences suggest that the proportion of different immune cell types in a tumor can
affect tumor growth and which treatments are effective.
Researchers often study tumors by measuring the expression of genes, i.e., which genes are
active in tumors. However, the proportion of different cell types in the tumor is often not measured
for tumors studied at the gene expression level.
Racle et al. have now demonstrated that a new computer-based tool can accurately detect all the
main cell types in a tumor directly from the expression of genes in this tumor. The tool is called
“Estimating the Proportion of Immune and Cancer cells” – or EPIC for short. It compares the level of
expression of genes in a tumor with a library of the gene expression profiles from specific cell types
that can be found in tumors and uses this information to predict how many of each type of cell are
present. Experimental measurements of several human tumors confirmed that EPIC’s predictions are
accurate.
EPIC is freely available online. Since the active genes in tumors from many patients have already
been documented together with clinical data, researchers could use EPIC to investigate whether the
cell types in a tumor affect how harmful it is or how well a particular treatment works on it. In the
future, this information could help to identify the best treatment for a particular patient and may
reveal new genes that cause malignant tumors to develop and grow.
DOI: https://doi.org/10.7554/eLife.26476.002
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Figure 1. Estimating the proportion of immune and cancer cells. (A) Schematic description of our method. (B) Matrix formulation of our algorithm,
including the uncharacterized cell types (red box) with no or very low expression of signature genes (green box). (C) Low dimensionality representation
(PCA based on the 1000 most variable genes) of the samples used to build the reference gene expression profiles from circulating immune cells (study
1 [Hoek et al., 2015], study 2 [Linsley et al., 2014], study 3 [Pabst et al., 2016]). (D) Low dimensionality representation (PCA based on the 1000 most
variable genes) of the tumor- infiltrating cell gene expression profiles from different patients. Each point corresponds to cell-type average per patient of
the single-cell RNA-Seq data of Tirosh et al. (2016) (requiring at least 3 cells of a given cell type per patient). Only samples from primary tumors and
non-lymphoid tissue metastases were considered. Projection of the original single-cell RNA-Seq data can be found in Figure 1—figure supplement 1.
DOI: https://doi.org/10.7554/eLife.26476.003
The following figure supplements are available for figure 1:
Figure supplement 1. Low dimensionality representation of the tumor-infiltrating cell samples.
DOI: https://doi.org/10.7554/eLife.26476.004
Figure supplement 2. Cell type mRNA content.
DOI: https://doi.org/10.7554/eLife.26476.005
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(Hoek et al., 2015; Linsley et al., 2014; Pabst et al., 2016) (CD4 T cells, CD8 T cells, B cells, NK
cells, Monocytes and Neutrophils) from a diverse set of patients analyzed in different centers (see
Materials and methods). Principal component analysis (PCA) of these data (Figure 1C) showed that
samples clustered first according to cell type and not according to experiment of origin, patient
age, disease status or other factors, suggesting that they could be used as bona fide reference
expression profiles across different patients. Reference gene expression profiles for each major
immune cell type were built from these RNA-Seq samples based on the median normalized counts
per gene and cell type. The variability in expression for each gene was also considered when predict-
ing the various cell proportions based on these reference profiles (see Materials and methods and
Supplementary file 1).
Immune cells differ in their gene expression profiles depending on their state and site of origin
(e.g., blood or tumors) (Ganesan et al., 2017; Speiser et al., 2016; Zheng et al., 2017). To study
the potential effect of these differences on our predictions, we established reference gene expres-
sion profiles of each major tumor-infiltrating immune cell type (i.e., CD4 T, CD8 T, B, NK, macro-
phages). We further derived reference profiles for stromal cells (i.e. cancer-associated fibroblasts
(CAFs)) and endothelial cells. These reference gene expression profiles were obtained as cell type
averages from the single-cell RNA-Seq data of melanoma patients from Tirosh and colleagues
(Tirosh et al., 2016), considering only samples from primary tumor and non-lymphoid tissue metas-
tasis (see Materials and methods and Supplementary file 2). As for circulating immune cell data,
principal component analysis of the tumor-infiltrating cells’ gene expression profiles showed that
samples clustered first according to cell type (Figure 1D and Figure 1—figure supplement 1, see
also results in [Tirosh et al., 2016]).
Cancer and non-malignant cell fraction predictions
Reference gene expression profiles from each of the immune and other non-malignant (i.e., stromal
and endothelial) cell types were then used to model bulk gene expression data as a linear combina-
tion of m different cell types (Figure 1B). To include cell types like cancer cells that show high vari-
ability across patients and tissues of origin, we further implemented in our algorithm the ability to
consider an uncharacterized cell population. Mathematically this was done by taking advantage of
the presence of gene markers of non-malignant cells that are not expressed in cancer cells. Impor-
tantly, we do not require our signature genes to be expressed in exactly one cell type, but only to
show very low expression in cancer cells. The mRNA proportion of each immune and other non-
malignant cell type was inferred using least-square regression, solving first our system of equations
for the marker genes (green box in Figure 1B, see Materials and methods). The fraction of cancer
cells was then determined as one minus the fraction of all non-malignant cell types. Cell markers
used in this work were determined by differential expression analysis based on our reference cell
gene expression profiles as well as gene expression data from non-hematopoietic tissues (see Mate-
rials and methods and Appendix 1—table 1). Finally, to account for different amounts of mRNA in
different cell types and enable meaningful comparison with flow cytometry and IHC data, we mea-
sured the mRNA content of all major immune cell types as well as of cancer cells (Figure 1—figure
supplement 2) and used these values to renormalize our predicted mRNA proportions (see Materi-
als and methods).
Validation in blood
We first tested our algorithm using three datasets comprising bulk RNA-Seq data from PBMC
(Hoek et al., 2015; Zimmermann et al., 2016) or whole blood (Linsley et al., 2014), as well as the
corresponding proportions of immune cell types determined by flow cytometry (Figure 2A). These
data were collected from various cancer-free human donors (see Materials and methods). Overall,
very accurate predictions were obtained by fitting reference profiles from circulating immune cells,
considering either all cell types together (Figure 2A) or each cell type separately (Figure 2—figure
supplement 1). When comparing with other widely used cell fraction prediction methods
(Becht et al., 2016; Gong and Szustakowski, 2013; Li et al., 2016; Newman et al., 2015;
Quon et al., 2013; Zhong et al., 2013), we observed a clear improvement (Figure 2B and Fig-
ure 2—figure supplement 1). Of note, the very high correlation values can partly result from the
broad range of different cell fractions in our data (Figure 2A) and we emphasize that these
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Figure 2. Predicting cell fractions in blood samples. (A) Predicted vs. measured immune cell proportions in PBMC (dataset 1 (Zimmermann et al.,
2016), dataset 2 (Hoek et al., 2015)) and whole blood (dataset 3 (Linsley et al., 2014)); predictions are based on the reference profiles from circulating
immune cells. (B) Performance comparison with other methods. Significant correlations are indicated above each bar (*p<0.05; **p<0.01; ***p<0.001).
(C) Predicted immune cells’ mRNA proportions (i.e., without mRNA renormalization step) vs. measured values in the same datasets. Correlations are
based on Pearson correlation; RMSE: root mean squared error. Proportions of cells observed experimentally are given in Supplementary file 3B-D.
DOI: https://doi.org/10.7554/eLife.26476.006
The following figure supplements are available for figure 2:
Figure supplement 1. Comparison of multiple cell fraction prediction methods in blood datasets.
DOI: https://doi.org/10.7554/eLife.26476.007
Figure supplement 2. Effect of including an mRNA renormalization step for multiple cell fraction prediction methods.
DOI: https://doi.org/10.7554/eLife.26476.008
Figure supplement 3. Effect of the various steps in EPIC on the prediction accuracy.
DOI: https://doi.org/10.7554/eLife.26476.009
Figure supplement 4. Results with or without known reference profiles for T cells for the cell fraction predictions from various methods.
DOI: https://doi.org/10.7554/eLife.26476.010
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correlation values should only be used to compare methods tested on the same datasets
(Figure 2B). The root mean squared error (RMSE), which is less dependent on such ‘outlier data
points’, shows also improved accuracy for EPIC compared to other methods (Figure 2—figure sup-
plement 1B).
The renormalization by mRNA content, which had not been considered in previous approaches,
appeared to be important for predicting actual cell fractions (Figure 2C). Moreover, we observed
that most other methods could also benefit from such a renormalization step, be it for the global
prediction of all cell types together or for the predictions of each cell type (Figure 2—figure supple-
ment 2). A conceptually related approach was developed by Baron et al. (2016), but the rescaling
was done on the gene expression reference profiles (in their case of pancreatic cells) based on the
total number of transcripts per cell type and the prediction of the proportion of pancreatic cells
from a bulk sample was carried out with CIBERSORT (Newman et al., 2015). For comparison pur-
pose, we implemented such an a priori renormalization step in EPIC as well, and observed similar
results than with the a posteriori renormalization (Figure 2—figure supplement 3).
With respect to the other methods, EPIC has two other main distinctive features: (i) it allows for a
cell type without a known reference gene expression profile (such a feature is also part of ISOpure
[Quon et al., 2013]) and (ii) it integrates information about the variability in each signature gene
from the reference gene expression profiles. The latter point slightly improves the prediction accu-
racy but to a lesser extent than the renormalization by mRNA (Figure 2—figure supplement 3). The
former point cannot be tested directly in the blood samples as only cell types with known reference
gene expression profiles are composing these samples. Therefore, to test the effect of including a
cell type without a known reference profile, we removed all the T cell subsets from the reference
gene expression profiles and predicted the proportion of the other cell types in the bulk samples,
allowing for one uncharacterized cell type in EPIC. As expected, the results from EPIC including or
not the T cell reference profiles remained nearly unchanged, while the other methods suffered from
this, except for DSA (Zhong et al., 2013) which is based only on signature genes and not reference
profiles (Figure 2—figure supplement 4). Such an advantage of EPIC is especially useful in the con-
text of tumor samples where in general no reference gene expression profile is available for the can-
cer cells.
Validation in solid tumors
To validate our predictions in tumors, we collected single cell suspensions from lymph nodes of four
metastatic melanoma patients (see Materials and methods). A fraction of the cell suspension was
used to measure the different cell type proportions with flow cytometry (CD4 T, CD8 T, B, NK, mela-
noma and other cells comprising mostly stromal and endothelial cells; Supplementary file 3A), and
the other fraction was used for bulk RNA sequencing (Figure 3—figure supplement 1). EPIC was
first run with reference profiles from circulating immune cells. We observed a remarkable agreement
between our predictions and experimentally determined cell fractions (Figure 3A). The high correla-
tion value is possibly driven by the two samples containing about 80% of melanoma cells, but we
stress that all predicted cell proportions fall nearly on the ‘y = x’ line. This clearly indicates that the
absolute cell fractions were correctly predicted for all cell types, as confirmed by a low RMSE. Of
note, the proportion of melanoma cells could be very accurately predicted even in the absence of a
priori information about their gene expression.
As a second validation, we compared EPIC predictions with IHC data from colon cancer
(Becht et al., 2016) (see Materials and methods). Although a limited number of immune cell types
had been assayed in this study, we observed a significant correlation between cell proportions mea-
sured by IHC and our predictions, except for the CD8 T cells (Figure 3B).
As a third validation, we used recent single-cell RNA-Seq data from 19 melanoma samples
(Tirosh et al., 2016). We applied EPIC on the average expression profile over all single cells for each
patient and compared the results with the actual cell fractions (see Materials and methods). Here
again, our predictions were consistent with the observed cell fractions, even for melanoma cells for
which we did not assume any reference gene expression profile (Figure 3C). Notably, the predicted
cell fractions from melanoma cells as well as from all other immune cell types fall nearly on the y = x
line, showing that not only the relative cell type proportions could be predicted but also the abso-
lute proportions for all cell types.
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We next compared these predictions to those obtained with reference profiles from tumor- infil-
trating cells, including also CAFs and endothelial cells (Figure 4). For the single-cell RNA-Seq data
(Figure 4C), we applied a leave-one-out procedure, to avoid using the same samples both to build
the reference profiles and the bulk RNA-Seq data used as input for the predictions (see Materials
and methods). Overall, predictions did not change much compared to those based on circulating
immune cell reference gene expression profiles (Figure 4), except for the IHC data where the pre-
dictions for CD8 T cells and macrophages clearly improved (Figure 4B). Moreover, we could observe
some differences between the results obtained from circulating immune cell reference gene expres-
sion profiles and those from tumor-infiltrating cell reference gene expression profiles, when consid-
ering the proportions from each cell type independently (Figures 3–4 and Figure 4—figure
supplement 1): (i) predictions for CD8 T cells and macrophages improved in the datasets of primary
tumors and non-lymph node metastases but not in the datasets from lymph node metastases; (ii)
Figure 3. Predicting cell fractions in solid tumors with reference profiles from circulating cells. (A) Comparison of EPIC predictions with our flow
cytometry data of lymph nodes from metastatic melanoma patients. (B) Comparison with immunohistochemistry data from colon cancer primary tumors
(Becht et al., 2016). (C) Comparison with single-cell RNA-Seq data (Tirosh et al., 2016) from melanoma samples either from lymphoid tissues or
primary and non-lymphoid metastatic tumors. Correlations are based on Pearson correlation. Proportions of cells observed experimentally are given in
Supplementary file 3A,E.
DOI: https://doi.org/10.7554/eLife.26476.011
The following figure supplement is available for figure 3:
Figure supplement 1. Sketch of the experiment designed to validate EPIC predictions starting from in vivo tumor samples.
DOI: https://doi.org/10.7554/eLife.26476.012
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predictions for B and NK cells displayed similar accuracy based on the circulating cells or tumor-infil-
trating cells profiles for all datasets; and (iii) CAFs and endothelial cells were not available for the
blood-based reference profiles but the proportion of these cells could be well predicted based on
the reference profiles constructed from tumor-infiltrating cells (Figure 4 and Figure 4—figure sup-
plement 1).
Benchmarking of other methods
We took advantage of our unique collection of independent validation datasets to benchmark other
methods for predictions of immune cell type fractions in human tumors. We first compared the
results of EPIC and ISOpure (Quon et al., 2013), which is the only other method that can consider
uncharacterized cell types and therefore predict the fraction of cancer and immune cell types based
only on RNA-seq data. EPIC displayed improved accuracy in all three datasets (Figure 5A, and Fig-
ure 5—figure supplements 1–4). To benchmark other methods, we then restricted our analysis to
the predictions of the different immune cell types (Figure 5B and Figure 5—figure supplements 1–
4). Predictions from EPIC were in general more accurate, especially when considering all cell types
Figure 4. Predictions with reference profiles from tumor-infiltrating cells. Same as Figure 3 but based on reference profiles built from the single-cell
RNA-Seq data of primary tumor and non-lymphoid metastatic melanoma samples from Tirosh et al. (2016). (A) Comparison with flow cytometry data
of lymph nodes from metastatic melanoma patients. (B) Comparison with IHC from colon cancer primary tumors (Becht et al., 2016). (C) Comparison
with single-cell RNA-Seq data (Tirosh et al., 2016). For primary tumor and non-lymphoid metastasis samples, a leave-one-out procedure was used (see
Materials and methods). Proportions of cells observed experimentally are given in Supplementary file 3A,E.
DOI: https://doi.org/10.7554/eLife.26476.013
The following figure supplement is available for figure 4:
Figure supplement 1. Comparison of EPIC results per cell type for gene expression reference profiles from circulating or tumor-infiltrating immune
cells.
DOI: https://doi.org/10.7554/eLife.26476.014
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Figure 5. Performance comparison with other methods in tumor samples. (A) Pearson correlation R-values between the cell proportions predicted by
EPIC and ISOpure and the observed proportions measured by flow cytometry or single-cell RNA-Seq (Tirosh et al., 2016), considering all cell types
together (i.e., B, CAFs, CD4 T, CD8 T, endothelial, NK, macrophages and cancer cells). (B) Same analysis as in Figure 5A but considering only immune
cell types (i.e., B, CD4 T, CD8 T, NK and macrophages) in order to include more methods in the comparison. (C) Analysis of ESTIMATE predictions in
the single-cell RNA-Seq dataset for the sum of all immune cells, the proportion of stromal cells (cancer-associated fibroblasts) and the proportion of
Figure 5 continued on next page
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together. Nevertheless, when restricting the comparisons to relative cell type proportions, some
methods like MCPcounter (Becht et al., 2016) and TIMER (Li et al., 2016) were quite consistent in
their predictions across the various datasets and showed similar accuracy as EPIC for the cell types
considered in these methods (Figure 5—figure supplements 1–4). Of note, MCPcounter could not
be included in the global prediction comparison as this method returns scores that are not compara-
ble between different cell types. Predictions from DSA (Zhong et al., 2013) were also quite accurate
when available, but in multiple cases some cell type proportions returned by the method were sim-
ply equal to 0 in all samples (Figure 5—figure supplements 1–4 – correlation values were replaced
by NA in these cases).
Immune, stromal and tumor purity scores (Yoshihara et al., 2013) based on gene set enrichment
analysis were also correlated with the total fraction of immune cells, stromal cells and the fraction of
cancer cells (correlation was not significant for the tumor purity score – Figure 5C and Figure 5—fig-
ure supplement 5). However, these correlations were considerably lower than those obtained with
our approach (Figure 5D and Figure 5—figure supplement 5). Moreover, such scores are less
quantitative and are thus more difficult to interpret with respect to actual cell type proportions.
Next, we performed some explorative analysis to test if such cell fraction prediction methods
could go further into the details of the T cell subsets. Based on the single-cell RNA-seq data from
Tirosh and colleagues (Tirosh et al., 2016), we identified CD4+ Treg and Thelper cells (see Materials
and methods), and built reference gene expression profiles for these cell types as we had done for
the other cell types. As before, a leave-1-out procedure at the patient level was used to predict the
proportions for these cell types based on the bulk samples constructed from this single-cell RNA-
seq data. We observed significant correlations, but the R-values are lower than before (Figure 5—
figure supplement 6), suggesting that we may be reaching the limits of cell fraction prediction
methods for cell types that show lower abundance and substantial transcriptional similarity. Of note,
CIBERSORT using either the LM22 signature or our newly derived signature did not perform better
than EPIC.
Discussion
By combining RNA-Seq profiles of all major immune and other non-malignant cell types established
from both circulating and tumor-infiltrating cells together with information about cell morphology
(i.e., mRNA content) and algorithmic developments to consider uncharacterized and possibly highly
variable cell types, EPIC overcomes several limitations of previous approaches to predict the fraction
of both cancer and immune or other non-malignant cell types from bulk tumor gene expression
data. From an algorithmic point of view, EPIC takes advantage of the fact that cancer cells, in gen-
eral, express no or only low levels of immune and stromal markers. Therefore the method can be
Figure 5 continued
cancer cells (cells identified as melanoma cells in Tirosh et al.). (D) Same as Figure 5C but for EPIC predictions of immune, stromal and cancer cells.
Significant correlations in (A–B) are indicated above each bar (*p<0.05; **p<0.01; ***p<0.001).
DOI: https://doi.org/10.7554/eLife.26476.015
The following figure supplements are available for figure 5:
Figure supplement 1. Comparison of multiple cell fraction prediction methods in tumor datasets.
DOI: https://doi.org/10.7554/eLife.26476.016
Figure supplement 2. Comparison of cell fraction prediction methods with flow cytometry data of melanoma tumors.
DOI: https://doi.org/10.7554/eLife.26476.017
Figure supplement 3. Comparison of cell fraction prediction methods with immunohistochemistry data in colon cancer data (Becht et al., 2016) for T
cell, CD8 T cell and macrophage infiltration values.
DOI: https://doi.org/10.7554/eLife.26476.018
Figure supplement 4. Comparison of cell fraction prediction methods with single-cell RNA-Seq data from melanoma tumors (Tirosh et al., 2016).
DOI: https://doi.org/10.7554/eLife.26476.019
Figure supplement 5. Comparison between ESTIMATE scores (A) and EPIC predictions (B) in our new flow cytometry dataset.
DOI: https://doi.org/10.7554/eLife.26476.020
Figure supplement 6. Predicting Thelper and Treg cell fractions in tumors.
DOI: https://doi.org/10.7554/eLife.26476.021
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broadly applied to most solid tumors, as confirmed by our validation in melanoma and colorectal
samples, but it will not be suitable for hematological malignancies like leukemia or lymphoma.
The accuracy of the predictions for some cell types might be sensitive to the origin or condition
of the immune cells used for establishing reference profiles. For instance, we observed that CD8 T
cells and macrophages from primary tumors and non-lymph node metastases samples were best
predicted using the reference profiles from tumor-infiltrating cells. This may be explained by the fact
that the reference profiles from circulating cells corresponded to resting CD8 T cells and monocytes
as only few activated C8 T cells and no macrophages are circulating in blood.
Overall, our results suggest that for primary tumors or non-lymphoid tissue metastases reference
gene expression profiles from tumor-infiltrating immune cells are more appropriate, while for lymph
node metastases, profiles from either circulating or tumor-infiltrating immune cells could be used.
One known limitation of cell fraction predictions arises when some cell types are present at very
low frequency (Shen-Orr and Gaujoux, 2013). Our results suggest that predictions of cell propor-
tions are reliable within an absolute error of about 8%, as estimated by the root mean squared error
(Figure 3 and Figure 4—figure supplement 1B). These estimates are consistent with the lower
detection limit proposed by other groups (Becht et al., 2016; Zhong et al., 2013) and may explain
why the relative proportions of NK cells, which are present at lower frequency in melanoma tumors
(Balch et al., 1990; Sconocchia et al., 2012), could not be predicted with accuracy comparable to
other cell types (Figure 4—figure supplement 1). While this may prevent applications of cell frac-
tion predictions in some tumor types that are poorly infiltrated, many other tumors, like melanoma
or colorectal cancer, display high level of infiltrating immune cells and the role of immune infiltrations
on tumor progression and survival appears to be especially important in these tumors
(Clemente et al., 1996; Fridman et al., 2012; Galon et al., 2006).
Another limitation of cell fraction predictions arises when considering cell types that show high
transcriptional similarity. For instance, Treg in Figure 5—figure supplement 6 could not be well pre-
dicted neither by EPIC nor CIBERSORT. This can be understood because the gene expression pro-
files of Thelper and Treg are highly similar with only a few genes expressed differently between the
two, making it harder for cell fraction prediction methods to work accurately. In addition, Treg were
present at a proportion lower than 10% in all samples (Supplementary file 3E). For such cases, gene
set enrichment approaches, although less quantitative, may be more convenient, possibly combining
them with the predictions obtained by EPIC for the main immune cell types.
Our predictions for the fraction of uncharacterized cells may include non-malignant cells, such as
epithelial cells from neighboring tissues in addition to cancer cells. Compared to recent algorithms
that first predict tumor purity based on exome sequencing data, and later infer the relative fraction
of immune cell types (Li et al., 2016), the predictions of EPIC for immune and stromal cells are likely
more quantitative because they can implicitly consider the presence of not only cancer cells but also
other non-malignant cells for which reference profiles are not available. Moreover, EPIC does not
require both exome and RNA-Seq data from the same tumor samples, thereby reducing the cost
and amount of experimental work for prospective studies, and broadening the scope of retrospec-
tive analyses of cancer genomics data to studies that only include gene expression data.
Recent technical developments in single-cell RNA-Seq technology enable researchers to directly
access information about both the proportion of all cell types together with their gene expression
characteristics (Carmona et al., 2017; Efroni et al., 2015; Jaitin et al., 2014; Singer et al., 2016;
Stegle et al., 2015; Tirosh et al., 2016). Such data are much richer than anything that can be
obtained with computational deconvolution of bulk gene expression profiles and this technology
may eventually replace standard gene expression analysis of bulk tumors. Nevertheless, it is impor-
tant to realize that, even when disregarding the financial aspects, single-cell RNA-Seq of human
tumors is still logistically and technically very challenging due to high level of cell death upon sample
manipulation (especially freezing and thawing) and high transcript dropout rates (Finak et al., 2015;
Saliba et al., 2014; Stegle et al., 2015). Moreover, one cannot exclude that some cells may better
survive the processing with microfluidics devices used in some single-cell RNA-Seq platforms,
thereby biasing the estimates of cell type proportions. It is therefore likely that bulk tumor gene
expression analysis will remain widely used for several years. Our work shows how we can exploit
recent single-cell RNA-Seq data of tumors obtained from a few patients to refine cell fraction predic-
tions in other patients that could not be analyzed with this technology, thereby overcoming some
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limitations of previous computational approaches that relied only on reference gene expression pro-
files from circulating immune cells.
In this work, we provide a detailed and biologically relevant validation of our predictions using
actual tumor samples from human patients analyzed with flow cytometry, IHC and single-cell RNA-
Seq. We note that the slightly lower agreement between our predictions and IHC data may be partly
explained by the fact that the exact same samples could not be used for both gene expression and
IHC analyses because of the incompatibility between the two techniques. Nevertheless, the overall
high accuracy of our predictions indicates that infiltrations of major immune cell types can be quanti-
tatively studied directly from bulk tumor gene expression data using computational approaches such
as EPIC.
EPIC can be downloaded as a standalone R package (https://github.com/GfellerLab/EPIC/
releases/tag/v1.1) (Racle, 2017) and can be used with reference gene expression profiles pre-com-
piled from circulating or tumor-infiltrating cells, or provided by the user. EPIC is also available as a
web application (http://epic.gfellerlab.org) where users can upload bulk samples gene expression
data and perform the full analysis.
Materials and methods
Code availability
EPIC has been written as an R package. It is freely available on GitHub (https://github.com/Gfeller-
Lab/EPIC; copy archived on https://github.com/elifesciences-publications/EPIC) for academic non-
commercial research purposes. Version v1.1 of the package was used for our analyses.
In addition to the R package, EPIC is available as a web application at the address: http://epic.
gfellerlab.org.
Prediction of cancer and immune cell type proportions
In EPIC, the gene expression of a bulk sample is modeled as the sum of the gene expression profiles
from the pure cell types composing this sample (Figure 1A,B). This can be written as (Venet et al.,
2001):
b¼C  p (1)
Where b is the vector of all n genes expressed from the bulk sample to deconvolve; C is a matrix
(n x m) of the m gene expression profiles from the different cell types; and p is a vector of the pro-
portions from the m cell types in the given sample (Figure 1B).
Matrix C consists of m-1 columns corresponding to various reference non-malignant cell types
whose gene expression profiles are known, and a last column corresponding to uncharacterized cells
(i.e. mostly cancer cells, but possibly also other non-malignant cell types not included in the refer-
ence profiles). EPIC assumes the reference gene expression profiles from the non-malignant cell
types are well conserved between patients. Such a hypothesis is supported by the analysis in
Figure 1C,D. The uncharacterized cells can be more heterogeneous between patients and EPIC
makes no assumption on them.
EPIC works with RNA-seq data, which is implicitly normalized. We use data normalized into tran-
scripts per million (TPM) because it has some properties needed for the full cell proportion predic-
tion to work, as will be shown in the next paragraphs. Therefore, instead of the raw data from



















Where b and C are the TPM-normalized bulk sample and reference cell gene expression profiles
respectively and li is the length of gene i.
Using these, Equation (1) is rewritten to:
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pj ¼ 1 (5)
In addition to p and C we also define p and C, which are the same except that they include the
normalized proportions and profiles from the reference cell types only (i.e. they have one less ele-
ment and one less column than p and C respectively).
Using these normalized quantities, EPIC then solves Equation (3) for a subset of ns equations cor-
responding to the ns signature genes (S) that are expressed by one or more of the reference cell
types but only expressed at a negligible level in the uncharacterized cells (Figure 1B). Previous
computational work (Clarke et al., 2010; Gosink et al., 2007) showed that the proportion from
uncharacterized cells in bulk samples could indeed be inferred with help of genes not expressed by
the uncharacterized cells. Importantly, cell-specific signature genes are well established and widely
used in flow cytometry to sort immune cells. Thus, EPIC solves the following system of equations:
biji2S ¼ ððC
* p*Þiþ
Cim  pmÞji2S ¼ ðC
* p*Þiji2S (6)
where the term corresponding to the uncharacterized cells (m) vanished thanks to the definition of
the signature genes (Cimji2S ﬃ 0).
The solution to Equation (6) can be estimated by a constrained least square optimization. EPIC
takes advantage of the known variability for each gene in the reference profile, to give weights in
the function to minimize:













Here, the weights, wi, give more importance to the signature genes with low variability in the ref-
erence gene expression profiles. In EPIC, these weights are given by:
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V
 
is the matrix of the TPM-based variability of each gene for each of the reference cells
(Supplementary files 1–2), " is a small number to avoid division by 0, and the term ’100 median uið Þ’
is used to avoid giving too much weight to few of the genes.





Since we used normalized gene expression data, values of p correspond actually to the fraction of
mRNA coming from each cell type, rather than the cell proportions. As the mRNA content per cell
type can vary significantly (Figure 1—figure supplement 2), the actual proportions of each cell type
can be estimated as:






where rj is the amount of RNA nucleotides in cell type j (or equivalently the total weight of RNA in
each cell type) and a is a normalization constant to have
P
pj ¼ 1.
Another method, DeMix (Ahn et al., 2013), starts from Equation (1) to estimate the proportion
and gene expression profile from cancer cells in mixed samples. In this method the mixed sample is
assumed to be composed only by two cell types: cancer cells (without any a priori known gene
expression profile) and normal cells (with known gene expression data, which can either come from
tumor-matched or unmatched samples). This method was developed for microarray data and shows
that it was important to use the raw data as input assuming it follows a log-normal distribution as is
the case for microarray, instead of working with log-transformed data like most other methods did.
DeMix estimates the variance of the gene expression in the normal samples and uses this in the max-
imum likelihood estimation to predict the cancer cell gene expression and proportions, using thus
implicitly a gene-specific weight for each gene. EPIC was derived for RNA-seq data and is directly
using linear (non-log) data. Notably, when solving the linear regression from Equation (7) in EPIC,
we are not assuming any specific distribution for the gene expression and the weights we give to
each gene are simply based on their interquartile range in the reference samples. Other measures of
gene variability could however be given as input into EPIC’s R-package. Contrary to DeMix, another
important assumption performed in EPIC is that our signature genes are not expressed by the can-
cer cells, so that we can easily estimate the proportion of multiple non-malignant cell types compos-
ing the bulk samples.
Flow cytometry and gene expression analysis of melanoma samples
Patients agreed to donate metastatic tissues upon informed consent, based on dedicated clinical
investigation protocols established according to the relevant regulatory standards. The protocols
were approved by the local IRB, that is, the ’Commission cantonale d’e´thique de la recherche sur
l’eˆtre humain du Canton de Vaud’. Lymph nodes (LN) were obtained from stage III melanoma
patients, by lymph node dissection that took place before systemic treatment. The LN from one
patient was from the right axilla and the LNs from the other three patients were from the iliac and
ilio-obturator regions (Appendix 2—table 1). Single cell suspensions were obtained by mechanical
disruption and immediately cryopreserved in RPMI 1640 supplemented with 40% FCS and 10%
DMSO. Single cell suspensions from four lymph nodes were thawed and used in parallel experiments
of flow cytometry and RNA extraction. In order to limit the number of dead cells after thawing, we
removed those cells using a dead cell removal kit (Miltenyi Biotech). Proportions of CD4 T (CD45+/
CD3+/CD4+/Melan-A-), CD8 T (CD45+/CD3+/CD8+/Melan-A ), NK (CD45+/CD56+/CD3 /CD33 /
Melan-A ), B (CD45+/CD19+/CD3 /CD33 /Melan-A ) and Melan-A expressing tumor cells
(Supplementary file 3A) were acquired via flow cytometry using the following antibodies: anti-CD3
BV711 (RRID:AB_2566035), anti-CD4 BUV737 (RRID:AB_2713927), anti-CD8 PE-Cy5 (RRID:AB_
2713928), anti-CD56 BV421 (RRID:AB_11218798), anti-CD19 APCH7 (RRID:AB_1645728), anti-CD33
PE-Cy7 (RRID:AB_2713932), anti-CD45 APC (RRID:AB_314400), anti-Melan-A FITC (RRID:AB_
2713930) and Fixable Viability Dye eFluor 455UV (eBioscience). Data was acquired on a BD LSR II
SORP flow cytometry machine (BD Bioscience). Analysis was performed using FlowJo (Tree Star).
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Cell proportions were based on viable cells only. In parallel total RNA was extracted using the
RNAeasy Plus mini kit (Qiagen) following the manufactures’ protocol. Starting material always con-
tained minimum 0.2  106 cells. RNA was quantified and integrity was analyzed using a Fragment
Analyser (Advanced Analytical). Total RNA from all samples used for sequencing had an RQN 7.
Libraries were obtained using the Truseq stranded RNA kit (Illumina). Single read (100 bp) was per-
formed using an Illumina HiSeq 2500 sequencer (Illumina).
Post processing of the sequencing was done using Illumina pipeline Casava 1.82. FastQC (version
0.10.1) was used for quality control. RNA-seq reads alignment to the human genome, hg19, and
TPM quantification were performed with RSEM (Li and Dewey, 2011) version 1.2.19, using Bowtie2
(Langmead and Salzberg, 2012) version 2.2.4 and Samtools (Li et al., 2009) version 1.2.
RNA-Seq data from this experiment have been deposited in NCBI’s Gene Expression Omnibus
(Edgar et al., 2002) and are accessible through GEO Series accession number GSE93722 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93722).
Amount of mRNA per cell type
Healthy donor peripheral blood was obtained through the blood transfusion center in Lausanne.
PBMCs were purified by density gradient using Lymphoprep (Axis-Shieldy). Mononuclear cells were
stained in order to sort monocytes, B, T and NK cells using the following antibodies: CD14 FITC
(RRID:AB_130992), CD19 PE (RRID:AB_2716572), CD3 APC (RRID:AB_130788), CD56 BV421 (RRID:
AB_11218798) and fixable live/dead near IR stain (ThermoFisher Scientific). 1  106 live cells from
each cell type were sorted using the BD FACS ARIA III (BD Biosciences). Total RNA was extracted
using the RNAeasy Plus mini kit (Qiagen) following the manufactures’ protocol and quantified using
a Fragment Analyser (Advanced Analytical). Values obtained are given in Figure 1—figure supple-
ment 2A.
The mRNA content for the cancer cells was estimated from the flow cytometry data described in
the previous section from the four patients with melanoma. For this we used the forward scatter
width, which is a good proxy of cell size and mRNA content (Padovan-Merhar et al., 2015;
Tzur et al., 2011), and observed that cancer cells had similar amount of mRNA than B, NK and T
cells (Figure 1—figure supplement 2B). We thus used a value of 0.4 pg of mRNA per cancer cell.
Public external datasets used in this study
. Dataset 1 was obtained from Zimmermann and colleagues (Zimmermann et al., 2016),
through ImmPort (http://www.immport.org), accession SDY67. It includes RNA-Seq samples
from PBMC of healthy donors before and after influenza vaccination. In addition, the original
flow cytometry results files were available, containing multiple immune cell markers. As an
independent validation of EPIC, we used the data from 12 pre-vaccination samples of healthy
donors and we computed the corresponding immune cell proportions from the flow cytometry
files merging the results from their innate and Treg panels (obtaining B, CD4 T, CD8 T, NK
cells and monocytes, Supplementary file 3B; Figure 2A)
. Dataset 2 was obtained from Hoek and colleagues (Hoek et al., 2015), GEO accession
GSE64655. This corresponds to RNA-Seq samples from two different donors. Samples have
been taken before an influenza vaccination and also 1, 3 and 7 days after the vaccination (56
samples in total). In their experiment, the authors measured RNA-Seq from bulk PBMC sam-
ples and also from sorted immune cells (B, NK, T cells, myeloid dendritic cells, monocytes and
neutrophils). In addition, flow cytometry was performed to measure the proportion of these
cell types in PBMC before the influenza vaccination (personally communicated by the authors;
Supplementary file 3C).
. Dataset 3 was obtained from Linsley and colleagues (Linsley et al., 2014), GEO accession
GSE60424. This dataset includes 20 donors (healthy donors and other donors with amyotro-
phic lateral sclerosis, multiple sclerosis, type one diabetes or sepsis), for a total of 134 samples.
RNA-Seq from these donors has been extracted from whole blood and sorted immune cells
(B, NK cells, monocytes, neutrophils, CD4 T and CD8 T cells). In addition to RNA-Seq data,
complete blood counts data were available for 5 of these donors (personally communicated by
the authors; Supplementary file 3D).
. Dataset 4 was obtained from Pabst and colleagues (Pabst et al., 2016), GEO accession
GSE51984. This includes RNA-Seq from five healthy donors. Samples are from total white
blood cells and sorted immune cells (B cells, granulocytes, monocytes and T cells).
Racle et al. eLife 2017;6:e26476. DOI: https://doi.org/10.7554/eLife.26476 15 of 25
Tools and resources Cancer Biology Computational and Systems Biology
. Colon cancer dataset was obtained from Becht and colleagues (Becht et al., 2016), GEO
accession GSE39582. This corresponds to microarrays of primary colon cancer tumors. In addi-
tion to gene expression data, immunohistochemistry data of CD3, CD8 and CD68 was avail-
able for 33 patients (personally communicated by the authors).
. Single-cell RNA-Seq data from tumor-infiltrating cells were obtained from Tirosh and col-
leagues (Tirosh et al., 2016), GEO accession GSE72056. This corresponds to 19 donors and
comprises primary tumors, lymph node metastasis or other lesions. It includes 4645 cells. Cell
type identity was taken from Tirosh et al. (2016) (B, NK, T cell, macrophage, CAFs, endothe-
lial cell, cancer cell as well as cells not assigned a specific cell type). Among the T cells, we
then defined subsets based on their gene expression: CD4 T cells (expressing CD4 but not
CD8A nor CD8B) and CD8 T cells (expressing CD8A or CD8B but not CD4). The other T cells
not corresponding to one of these two groups were removed from further analyses. We fur-
ther defined among the CD4 T cells: Treg (expressing either FOXP3 or CD25 above the
median among CD4 T cells) and Thelper (those CD4 T cells not belonging to Treg group). In
silico reconstructed bulk samples from each donor were obtained as the average per gene
from all samples of the given donor. The corresponding cell fractions from these bulk samples
were obtained as the number of cells from each cell type divided by the total number of cells
(Supplementary file 3E). In the results, we split this dataset in two depending on the origin of
the biopsies: lymphoid tissues for samples obtained from lymph node and spleen metastases,
vs. the rest of samples, which were obtained from primary tumor and other metastases.
For the above datasets 2 and 3, we obtained raw fastq files. RNA-seq reads alignment to the human
genome, hg19, and TPM quantification were performed with RSEM (Li and Dewey, 2011) version
1.2.19, using Bowtie2 (Langmead and Salzberg, 2012) version 2.2.4 and Samtools (Li et al., 2009)
version 1.2.
For the other datasets, we directly obtained the summary counts data from the respective studies
without mapping the reads by ourselves, and we transformed these counts to TPM wherever
necessary.
Reference gene expression profiles from circulating cells
Reference gene expression profiles of sorted immune cells from peripheral blood were built from
the datasets 2, 3 and 4 described in previous section. We verified no experimental biases were pres-
ent in these data through unsupervised clustering of the samples, with help of a principal component
analysis based on the normalized expression from the 1000 most variable genes (Figure 1C).
The median value of TPM counts was computed per cell type and per gene. Similarly, the inter-
quartile range of the TPM counts was computed per cell type and gene, as a measure of the variabil-
ity of each gene expression in each cell type. Values of these reference profiles are given in
Supplementary file 1). Granulocytes from dataset 4 and neutrophils from datasets 2 and 3 were
combined to build the reference profile for neutrophils (neutrophils constitute more than 90% of
granulocytes). No reference profile was built for the myeloid dendritic cells as only few samples of
these sorted cells existed and they were all from the same experiment. Monocytes are not found in
tumors but instead there are macrophages, mostly from monocytic lineage, that are infiltrating
tumors and that are not found in blood. For this reason, we also used the monocyte reference gene
expression profile as a proxy for macrophages when applying EPIC to tumor samples. Such an
assumption gave coherent results as observed in the results.
Reference profiles from tumor-infiltrating cells
We also built gene expression reference profiles from tumor-infiltrating cells. These are based on
the single-cell RNA-Seq data from Tirosh and colleagues (Tirosh et al., 2016) described above. We
only used the non-lymphoid tissue samples to build these tumor-infiltrating cell’s profiles, avoiding
in this way potential ‘normal immune cells’ present in the lymph nodes and spleen. These reference
profiles (Supplementary file 2) were built in the same way as described above for the reference pro-
files of circulating immune cells, but based on the mean and standard deviation instead of median
and interquartile range respectively, due to the nature of single-cell RNA-Seq data and gene drop-
out present with such technique.
When testing EPIC with these profiles for the single-cell RNA-Seq datasets, for the samples of pri-
mary tumor and other non-lymph node metastases, a leave-one-out procedure was applied: for each
donor we built reference cell profiles based only on the data coming from the other donors.
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Cell marker gene identification
EPIC relies on signature genes that are expressed by the reference cells but not by the uncharacter-
ized cells (e.g., cancer cells). For each reference cell type, we thus built a list of signature genes
through the following steps:
1. The samples (from the peripheral blood datasets) from each immune cell type were tested for
overexpression against:
a. the samples from each other immune cell of peripheral blood datasets (1 cell type vs. 1
other cell type at a time);
b. the samples of the Illumina Human Body Map 2.0 Project (ArrayExpress ID: E-MTAB-513)
considering all non-immune related tissues;
c. the samples from GTEx (GTEx Consortium, 2015) from each of the following tissues (one
tissue at a time): adipose subcutaneous; bladder; colon-transverse; ovary; pancreas; testis
(data version V6p).
2. Only genes overexpressed in the given cell type with an adjusted p-value<0.01 for all these
tests were kept. Conditions 1b) and 1c) are there to ensure signature genes are expressed in
the immune cells and no other tissues.
3. The genes that passed 2) were then ranked by the fold change from the overexpression tests
to preselect the genes showing the biggest difference between the various cell types.
4. The list of genes was then manually curated, comparing the expression of the genes per cell
type in the peripheral blood datasets and the tumor-infiltrating cells dataset: only genes
expressed at similar levels between the blood and tumor-infiltrating cells were kept (to avoid
differences due to exhaustion phenotype for example). Genes expressed at much higher levels
than the other genes were also removed from the signature as these could have biased the
least-square optimization towards good predictions for these genes only.
5. In addition to CD4 and CD8 T cells signatures, we built a signature list of general T cell genes
in the same way as described above, and it contains genes expressed at similar levels in the
two T cell subtypes. This general T cell signature is also part of EPIC, even when predicting the
proportions of the T cell subsets.
6. For the tumor-infiltrating cell reference profiles, signature genes from CAFs, endothelial cells
and macrophages were also needed. These were built in a similar way than above, considering
the overexpression from each of these cell types against each other cell type from the tumor-
infiltrating cells data.
All the differential expression tests were performed with DESeq2 (Love et al., 2014).
Appendix 1—table 1 summarizes the full list of signature genes per cell type.
Prediction of cell proportions in bulk samples with other tools
We compared EPIC’s predictions with those from various cell fraction prediction methods. These
other methods were run with the following packages (using the default options when possible):
. CIBERSORT (Newman et al., 2015) (R package version 1.03) was run based on two different
gene expression reference profiles:
 based on the LM22 reference profiles derived in (Newman et al., 2015). For comparison
with the experimentally measured cell proportions, we summed together the sub-types
predictions of CIBERSORT within each major immune cell type.
 based on the reference profiles and signature genes we derived here for EPIC.
. DeconRNASeq (v1.16) (Gong and Szustakowski, 2013) does not contain immune cell refer-
ence profiles and we used the reference profiles we derived here as well as the corresponding
signature genes. We present the results with ‘use.scale’ parameter set to FALSE, which usually
gave better results.
. DSA (Zhong et al., 2013) only needs a gene signature per cell type to estimate the proportion
of cells in multiple bulk samples together. We used the implementation of DSA found in Cell-
Mix (Gaujoux and Seoighe, 2013) R package (version 1.6.2). As DSA needs many samples to
estimate simultaneously the proportions of cells in these samples, we considered all the PBMC
samples from Hoek et al. data when fitting this dataset (eight samples) and all whole blood
samples from Linsley et al. data when fitting this other dataset (20 samples), even though the
cell proportions have been measured experimentally only for 2 and 5 samples respectively. For
the gene signature, we used the same genes as those used for EPIC (Appendix 1—table 1;
markers of B cells, CD4 T cells, CD8 T cells, monocytes, neutrophils and NK cells for the
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predictions in the blood datasets; markers of B cells, CAFs, CD4 T cells, CD8 T cells, endothe-
lial cells, macrophages, and NK cells for the predictions in solid tumors).
. ISOpure (Quon et al., 2013) estimates the profile and proportion of cancer cells by comparing
many bulk samples containing cancer cells and many healthy bulk samples of the same tissue.
Although the primary goal is not to compute the proportions of the different cell types com-
posing a sample, cell fractions can still be obtained with this method. In particular, one output
of ISOpure is how much each of the healthy reference samples is contributing to a given bulk
sample. Instead of using bulk healthy samples, we used our cell reference profiles, so that
each ‘reference sample’ corresponded to a different cell type. These reference samples and
the bulk samples were then subsetted by the same signature genes that we derived for EPIC.
ISOpure was then run based on these data. The contribution of each cell type was taken as the
relative contribution outputted by ISOpure from each of the reference cell sample. The R
implementation ISOpureR (Anghel et al., 2015) version 1.0.21 was used.
. MCP-counter (Becht et al., 2016) (R package version 1.1.0) was run with the ‘HUGO_symbols’
chosen as features or with ‘affy133P2_probesets’ for the microarray-based IHC dataset.
. TIMER (Li et al., 2016) predictions were obtained by slightly adapting the available source
code. The reference profiles available in TIMER were used directly. In addition to bulk gene
expression, tumor purity estimates based on DNA copy number variation are needed in TIMER
to refine the gene signature. As this information is not available in our benchmarking datasets,
we kept all the original immune gene signatures for the predictions in blood. For the tumor
datasets, we used the gene signatures obtained from the TCGA data for melanoma or colorec-
tal cancer depending on the origin of cancer.
. ESTIMATE (Yoshihara et al., 2013) was run with their R package version 1.0.11.
For CIBERSORT, DeconRNASeq and ISOpure, when run based on our gene expression reference
profiles, we used the reference profiles from peripheral blood immune cells for the predictions in
blood and the reference profiles from tumor-infiltrating cells for the predictions in solid tumors.
List of abbreviations
CAFs: cancer-associated fibroblasts; EPIC: acronym for our method to ‘Estimate the Proportion of
Immune and Cancer cells’; GEO: Gene Expression Omnibus; IHC: immunohistochemistry; PCA: prin-
cipal component analysis; RMSE: root mean squared error; TCGA: The Cancer Genome Atlas; TPM:
transcripts per million.
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. Supplementary file 1. Gene expression reference profiles, built from TPM (transcripts per million)
normalized RNA-Seq data of immune cells sorted from blood as described in the Materials and
methods: ‘Reference gene expression profiles from circulating cells’. The file includes two sheets: (A)
the reference gene expression values; (B) the gene variability relating to the reference profile. Col-
umns indicate the reference cell types; rows indicate the gene names.
DOI: https://doi.org/10.7554/eLife.26476.022
. Supplementary file 2. Gene expression reference profiles built from tumor-infiltrating cells obtained
from TPM normalized single-cell RNA-Seq data as described in the Materials and methods: ‘Refer-
ence profiles from tumor-infiltrating cells’. The file includes two sheets: (A) the reference gene
expression values; (B) the gene variability relating to the reference profile. Columns indicate the ref-
erence cell types; rows indicate the gene names.
DOI: https://doi.org/10.7554/eLife.26476.023
. Supplementary file 3. Proportion of cells measured in the different datasets: (A) this study; (B) data-
set 1 (Zimmermann et al., 2016); (C) dataset 2 (Hoek et al., 2015); (D) dataset 3 (Linsley et al.,
2014); and (E) single-cell RNA-Seq dataset (Tirosh et al., 2016). The ‘Other cells’ type corresponds
always to the rest of the cells that were not assigned to one of the given cell types from the tables.
DOI: https://doi.org/10.7554/eLife.26476.024
. Transparent reporting form
DOI: https://doi.org/10.7554/eLife.26476.025
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Appendix 1
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Appendix 1—table 1. Gene markers used per cell type. Only markers of cell types present in
the respective reference gene expression profiles are used.
Cell type Genes markers
B cells BANK1, CD79A, CD79B, FCER2, FCRL2, FCRL5, MS4A1, PAX5, POU2AF1, STAP1, TCL1A
CAFs
ADAM33, CLDN11, COL1A1, COL3A1, COL14A1, CRISPLD2, CXCL14, DPT, F3, FBLN1,
ISLR, LUM, MEG3, MFAP5, PRELP, PTGIS, SFRP2, SFRP4, SYNPO2, TMEM119
CD4 T cells ANKRD55, DGKA, FOXP3, GCNT4, IL2RA, MDS2, RCAN3, TBC1D4, TRAT1
CD8 T cells CD8B, HAUS3, JAKMIP1, NAA16, TSPYL1
Endothelial
cells
CDH5, CLDN5, CLEC14A, CXorf36, ECSCR, F2RL3, FLT1, FLT4, GPR4, GPR182, KDR,
MMRN1, MMRN2, MYCT1, PTPRB, RHOJ, SLCO2A1, SOX18, STAB2, VWF
Macrophages
APOC1, C1QC, CD14, CD163, CD300C, CD300E, CSF1R, F13A1, FPR3, HAMP, IL1B,
LILRB4, MS4A6A, MSR1, SIGLEC1, VSIG4
Monocytes CD33, CD300C, CD300E, CECR1, CLEC6A, CPVL, EGR2, EREG, MS4A6A, NAGA, SLC37A2
Neutrophils
CEACAM3, CNTNAP3, CXCR1, CYP4F3, FFAR2, HIST1H2BC, HIST1H3D, KY, MMP25,
PGLYRP1, SLC12A1, TAS2R40
NK cells CD160, CLIC3, FGFBP2, GNLY, GNPTAB, KLRF1, NCR1, NMUR1, S1PR5, SH2D1B
T cells BCL11B, CD5, CD28, IL7R, ITK, THEMIS, UBASH3A
DOI: https://doi.org/10.7554/eLife.26476.027
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Appendix 2
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Appendix 2—table 1. Characteristics of the patients with metastatic melanoma and
corresponding lymph node samples.
Patient Age (years) Gender Tissue
LAU125 59 male iliac lymph node
LAU355 70 female iliac-obturator lymph node
LAU1255 87 male axillary lymph node
LAU1314 81 male iliac-obturator lymph node
DOI: https://doi.org/10.7554/eLife.26476.029
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